Comparing Nautilus Biotechnology (NASDAQ:NAUT) & Prenetics Global (NASDAQ:PRE)

Nautilus Biotechnology (NASDAQ:NAUT) and Prenetics Global (NASDAQ:PRE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Risk and Volatility

Nautilus Biotechnology has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Prenetics Global has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500.

Profitability

This table compares Nautilus Biotechnology and Prenetics Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-27.11%	-23.50%
Prenetics Global	-282.96%	-10.76%	-8.79%

Institutional and Insider Ownership

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 25.0% of Prenetics Global shares are owned by institutional investors. 40.5% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 7.8% of Prenetics Global shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Nautilus Biotechnology and Prenetics Global, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	0	1	1	0	2.50
Prenetics Global	0	0	1	0	3.00

Nautilus Biotechnology presently has a consensus price target of $4.50, suggesting a potential upside of 77.17%. Prenetics Global has a consensus price target of $9.00, suggesting a potential upside of 83.67%. Given Prenetics Global’s stronger consensus rating and higher possible upside, analysts plainly believe Prenetics Global is more favorable than Nautilus Biotechnology.

Valuation & Earnings

This table compares Nautilus Biotechnology and Prenetics Global’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$63.67 million	($0.55)	-4.62
Prenetics Global	$23.23 million	1.93	-$62.72 million	($4.45)	-1.10

Prenetics Global has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.

Summary

Prenetics Global beats Nautilus Biotechnology on 7 of the 12 factors compared between the two stocks.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.